- Home
- MG vs CRDF Comparison
MG vs CRDF Comparison
Compare MG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MG
- CRDF
- Stock Information
- Founded
- MG 1978
- CRDF 1999
- Country
- MG United States
- CRDF United States
- Employees
- MG N/A
- CRDF N/A
- Industry
- MG Military/Government/Technical
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MG Consumer Discretionary
- CRDF Health Care
- Exchange
- MG Nasdaq
- CRDF Nasdaq
- Market Cap
- MG 251.0M
- CRDF 233.5M
- IPO Year
- MG 2009
- CRDF N/A
- Fundamental
- Price
- MG $7.80
- CRDF $2.64
- Analyst Decision
- MG
- CRDF Strong Buy
- Analyst Count
- MG 0
- CRDF 6
- Target Price
- MG N/A
- CRDF $11.92
- AVG Volume (30 Days)
- MG 92.3K
- CRDF 3.0M
- Earning Date
- MG 08-06-2025
- CRDF 07-29-2025
- Dividend Yield
- MG N/A
- CRDF N/A
- EPS Growth
- MG N/A
- CRDF N/A
- EPS
- MG 0.47
- CRDF N/A
- Revenue
- MG $706,813,000.00
- CRDF $545,000.00
- Revenue This Year
- MG $0.81
- CRDF N/A
- Revenue Next Year
- MG $15.30
- CRDF N/A
- P/E Ratio
- MG $16.56
- CRDF N/A
- Revenue Growth
- MG N/A
- CRDF N/A
- 52 Week Low
- MG $7.06
- CRDF $2.01
- 52 Week High
- MG $12.44
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- MG 40.90
- CRDF 34.68
- Support Level
- MG $7.81
- CRDF $2.31
- Resistance Level
- MG $8.05
- CRDF $4.52
- Average True Range (ATR)
- MG 0.21
- CRDF 0.37
- MACD
- MG -0.04
- CRDF -0.21
- Stochastic Oscillator
- MG 10.17
- CRDF 14.67
About MG Mistras Group Inc
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.